Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 84,132	$ 362,266
Securities carried at fair value	228,354	0
Prepaid expenses and other current assets	11,122	11,903
Short term notes receivable	0	913
Total current assets	323,608	375,082
Property and equipment, net	303	149
Equity Method Investments	1,162	16,131
Other investments	9,233	11,628
Long term notes receivable - related parties	7,040	3,835
Other assets	7,590	7,341
Total assets	348,936	414,166
Current liabilities:
Accounts payable	2,738	6,004
Accrued liabilities	18,913	14,829
Current portion of contingent consideration liability - related parties	0	51
Other current liabilities	306	51
Total current liabilities	21,957	20,935
Non-current portion of contingent consideration liability - related parties	2,338	2,432
Convertible promissory notes - related parties, net of discounts and deferred issuance costs	619	743
Other liabilities	3,900	4,097
Total liabilities	28,814	28,207
Commitments and contingencies (Note 15)
Stockholders' equity:
Common stock, 0.10 par value ($0.12 par value at June 30, 2022 and December 31, 2021, respectively); 750,000,000 shares authorized at June 30, 2022 and December 31, 2021, respectively; 161,727,785 and 160,677,001 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively	18,114	18,002
Additional paid-in capital	746,042	725,045
Accumulated other comprehensive loss	(21,191)	(8,336)
Accumulated deficit	(431,290)	(357,803)
Total stockholders' equity attributable to ATAI Life Sciences N.V. stockholders	311,675	376,908
Noncontrolling interests	8,447	9,051
Total stockholders' equity	320,122	385,959
Total liabilities and stockholders' equity	$ 348,936	$ 414,166